The Doctor’s Lounge Podcast's banner

The Doctor’s Lounge Podcast

@DRsLoungePod • 3,306 subscribers

This is where scalpels meet systems and physicians say what they really think. @anish_koka @DrDiGiorgio @sdixitmd @drdanchoi

Shorts

"If you're just going to pay Medicare rates anyway, every physician in this country is just going to wash their hands of the whole deal." Rep. Tom Oliverson, MD, on why a large part of the medical community opposes Medicare for All: "We're just not doing this anymore."

"If you're just going to pay Medicare rates anyway, every physician in this country is just going to wash their hands of the whole deal." Rep. Tom Oliverson, MD, on why a large part of the medical community opposes Medicare for All: "We're just not doing this anymore."

25,815 views

Videos

Anya Rossi

sweetdream.ai

SweetDream.ai•Sponsored•Livecam

Watch Anya Live

Anya is streaming live right now! Join her private show and enjoy exclusive content.

Exclusive private shows

1.2k viewers online

Private Show

Join now for exclusive access

Free preview available • Premium content

Cardiac surgeons are trying to compete with cardiologists on convenience. They're going to lose. A smaller incision doesn't make it minimally invasive. It makes it minimal access. And a mini-AVR? It actually hurts more than a standard sternotomy because you open the sternum AND break into the rib cage. "If you think you can compete convenience-wise with a cardiologist who does stents when you do a CABG and your incision is small, you're not fooling anyone." The game surgeons should be playing isn't incision size. It's durability. Longevity. Freedom from re-intervention. That's the competition cardiologists can't win. But surgeons keep fighting on the wrong turf.

Cardiac surgeons are trying to compete with cardiologists on convenience. They're going to lose. A smaller incision doesn't make it minimally invasive. It makes it minimal access. And a mini-AVR? It actually hurts more than a standard sternotomy because you open the sternum AND break into the rib cage. "If you think you can compete convenience-wise with a cardiologist who does stents when you do a CABG and your incision is small, you're not fooling anyone." The game surgeons should be playing isn't incision size. It's durability. Longevity. Freedom from re-intervention. That's the competition cardiologists can't win. But surgeons keep fighting on the wrong turf.

The Doctor’s Lounge Podcast

99,859 views • 5 months ago

Medical students think being a cardiac surgeon means waking up, going to the OR, doing something incredible, and going home. That couldn't be further from the truth. And we're not correcting them. Three different pathways to become a cardiac surgeon. 5-2. 4-3. I-6. Programs change their pathway depending on the year. Depending on who came back from the lab. "There's no other field like this. If you want to become a pilot, there is a path. With cardiac surgery, there are three different paths — and programs change them depending on the year." And the work hour restrictions meant to protect residents? "I'm convinced they hurt the residents." Residency is supposed to be a simulation of the rest of your life. We're not giving them that simulation. We're giving them a highlight reel. And then sending them out to practice.

Medical students think being a cardiac surgeon means waking up, going to the OR, doing something incredible, and going home. That couldn't be further from the truth. And we're not correcting them. Three different pathways to become a cardiac surgeon. 5-2. 4-3. I-6. Programs change their pathway depending on the year. Depending on who came back from the lab. "There's no other field like this. If you want to become a pilot, there is a path. With cardiac surgery, there are three different paths — and programs change them depending on the year." And the work hour restrictions meant to protect residents? "I'm convinced they hurt the residents." Residency is supposed to be a simulation of the rest of your life. We're not giving them that simulation. We're giving them a highlight reel. And then sending them out to practice.

The Doctor’s Lounge Podcast

91,039 views • 5 months ago

Academic Medicine published a study. Minority residents were underperforming across multiple top programs — Harvard, UVA, Emory. The paper offered three explanations: faculty racism, a flawed assessment tool, or an unwelcoming environment. Dr. Goldfarb tweeted a fourth: could it be a performance problem? That one sentence ended his 50-year career at Penn.

Academic Medicine published a study. Minority residents were underperforming across multiple top programs — Harvard, UVA, Emory. The paper offered three explanations: faculty racism, a flawed assessment tool, or an unwelcoming environment. Dr. Goldfarb tweeted a fourth: could it be a performance problem? That one sentence ended his 50-year career at Penn.

The Doctor’s Lounge Podcast

60,242 views • 3 months ago

George Tolis: TAVR, Broken Training, and What's Really Wrong With Cardiac Surgery. Dr. George Tolis, section chief of coronary and general cardiac surgery at Brigham and Women's Hospital, joins Drs. Koka and DiGiorgio for a wide-ranging conversation on the state of cardiac surgery. He makes the case that TAVR — while genuinely transformative for the right patient — is being systematically applied too broadly, driven by industry incentive and the erosion of meaningful surgical consent. He discusses his collaboration with John Ioannidis that found no statistically significant mortality benefit for any new cardiac surgery technique introduced over the past 35 years, the paper's rejection by every major surgical journal, and what he paid out of pocket to make it open access. The conversation moves to the collapse of surgical training — fragmented pathways, work hour restrictions that leave residents unprepared for attending life, an academic promotion system that ignores teaching, and a culture that routes incompetent trainees around rather than out — and closes with a brief on Vasily Kolesov, the Soviet surgeon from Leningrad who performed the world's first documented coronary bypass years before Favaloro, and whose work was buried by the Cold War. Chapter Markers 00:00 Introduction 01:02 Air-cooled VWs, concert piano, and how Dr. Tolis got here 02:40 TAVR: genuine breakthrough or being abused? 08:02 Finding the TAVR threshold — and why informed consent is the real problem 11:46 Collaborating with John Ioannidis: no mortality benefit for 35 years of new techniques 20:02 Why the major surgical journals wouldn't touch the paper 21:52 Minimally invasive surgery: minimal access vs. minimally invasive 26:24 When do CABG survival curves diverge — and what does it mean? 30:05 Surgeons signing off on TAVRs in young patients 33:51 Health system economics and the heart team dynamic 37:50 How to actually pick a good surgeon (ask the scrub nurses) 40:36 Cardiac surgery training: the three pathways problem 44:04 Work hour restrictions and the residency simulation gap 51:16 General surgery is like MTV — they don't operate anymore 53:21 A resident who finished training without ever applying a cross-clamp 56:34 How to evaluate if a program actually trains 59:27 Academic promotion has nothing to do with teaching 01:01:33 Dr. Tolis's resident outcomes database and three papers nobody cared about 01:05:32 The training timeline: finishing at 49, no runway left 01:07:08 One-size-fits-all RRC rules for cardiac surgery and psychiatry 01:09:16 Cardiac surgery as a disposition, not a therapy 01:12:24 When ECMO becomes the final common path 01:13:38 How you become nationally recognized without being a good surgeon 01:17:16 Vasily Kolesov: the Soviet surgeon who did the first bypass Co-Host Handles Anish Koka, MD and Anthony DiGiorgio, DO, MHA Show Handle The Doctor’s Lounge Podcast Subscribe Links Spotify: Apple Podcasts: YouTube:

George Tolis: TAVR, Broken Training, and What's Really Wrong With Cardiac Surgery. Dr. George Tolis, section chief of coronary and general cardiac surgery at Brigham and Women's Hospital, joins Drs. Koka and DiGiorgio for a wide-ranging conversation on the state of cardiac surgery. He makes the case that TAVR — while genuinely transformative for the right patient — is being systematically applied too broadly, driven by industry incentive and the erosion of meaningful surgical consent. He discusses his collaboration with John Ioannidis that found no statistically significant mortality benefit for any new cardiac surgery technique introduced over the past 35 years, the paper's rejection by every major surgical journal, and what he paid out of pocket to make it open access. The conversation moves to the collapse of surgical training — fragmented pathways, work hour restrictions that leave residents unprepared for attending life, an academic promotion system that ignores teaching, and a culture that routes incompetent trainees around rather than out — and closes with a brief on Vasily Kolesov, the Soviet surgeon from Leningrad who performed the world's first documented coronary bypass years before Favaloro, and whose work was buried by the Cold War. Chapter Markers 00:00 Introduction 01:02 Air-cooled VWs, concert piano, and how Dr. Tolis got here 02:40 TAVR: genuine breakthrough or being abused? 08:02 Finding the TAVR threshold — and why informed consent is the real problem 11:46 Collaborating with John Ioannidis: no mortality benefit for 35 years of new techniques 20:02 Why the major surgical journals wouldn't touch the paper 21:52 Minimally invasive surgery: minimal access vs. minimally invasive 26:24 When do CABG survival curves diverge — and what does it mean? 30:05 Surgeons signing off on TAVRs in young patients 33:51 Health system economics and the heart team dynamic 37:50 How to actually pick a good surgeon (ask the scrub nurses) 40:36 Cardiac surgery training: the three pathways problem 44:04 Work hour restrictions and the residency simulation gap 51:16 General surgery is like MTV — they don't operate anymore 53:21 A resident who finished training without ever applying a cross-clamp 56:34 How to evaluate if a program actually trains 59:27 Academic promotion has nothing to do with teaching 01:01:33 Dr. Tolis's resident outcomes database and three papers nobody cared about 01:05:32 The training timeline: finishing at 49, no runway left 01:07:08 One-size-fits-all RRC rules for cardiac surgery and psychiatry 01:09:16 Cardiac surgery as a disposition, not a therapy 01:12:24 When ECMO becomes the final common path 01:13:38 How you become nationally recognized without being a good surgeon 01:17:16 Vasily Kolesov: the Soviet surgeon who did the first bypass Co-Host Handles Anish Koka, MD and Anthony DiGiorgio, DO, MHA Show Handle The Doctor’s Lounge Podcast Subscribe Links Spotify: Apple Podcasts: YouTube:

The Doctor’s Lounge Podcast

69,129 views • 5 months ago

Anthony DiGiorgio on why doctors stop speaking up: "Why do you care, Doctor? It's just another five clicks in Epic. It's just another checkbox. It's just another form." But it all adds up. Stop fighting it, and you get a kludgeocracy — endless checkboxes, endless forms. And when doctors raise real patient safety concerns? They get labeled disruptive. Not a team player. The conversation shifts to the 75 other things on the checklist they didn't do. 🎧 Full episode:

Anthony DiGiorgio on why doctors stop speaking up: "Why do you care, Doctor? It's just another five clicks in Epic. It's just another checkbox. It's just another form." But it all adds up. Stop fighting it, and you get a kludgeocracy — endless checkboxes, endless forms. And when doctors raise real patient safety concerns? They get labeled disruptive. Not a team player. The conversation shifts to the 75 other things on the checklist they didn't do. 🎧 Full episode:

The Doctor’s Lounge Podcast

20,271 views • 1 month ago

"Old cranky guy who walked to school in the snow barefoot." That's the pushback he expects. But here's the evidence: More and more cardiac surgery graduates are doing "extra training" after they finish. Not because they want to specialize further. Because they never got the basics. One resident. Reputable program. Finished their entire training. Never applied a cross-clamp. Not once. "That's what the attending does from the other side of the table." So they finished. Got their certificate. And left unprepared to operate independently. "That is not training. That is complete insanity." This isn't an anecdote about one bad program. It's what happens when you protect residents so much that you forget to actually train them.

"Old cranky guy who walked to school in the snow barefoot." That's the pushback he expects. But here's the evidence: More and more cardiac surgery graduates are doing "extra training" after they finish. Not because they want to specialize further. Because they never got the basics. One resident. Reputable program. Finished their entire training. Never applied a cross-clamp. Not once. "That's what the attending does from the other side of the table." So they finished. Got their certificate. And left unprepared to operate independently. "That is not training. That is complete insanity." This isn't an anecdote about one bad program. It's what happens when you protect residents so much that you forget to actually train them.

The Doctor’s Lounge Podcast

66,034 views • 5 months ago

Vinay Prasad: COVID, the FDA, and Why Journalism Keeps Getting Medicine Wrong Dr. Vinay Prasad joins the Doctors Lounge in a recorded in person conversation that moves from his time at the FDA to bigger questions about evidence, incentives, and trust in medicine. The discussion focuses on how regulatory agencies actually function, why public health debates have become so politicized, and whether the current healthcare funding model rewards good care or just expensive care. Timestamps: 00:16 - Why the FDA conversation matters now 02:49 - Why Vinay accepted the DC job 04:02 - What can actually change inside the FDA 05:39 - The Exondys approval and commissioner authority 07:22 - Do appointees really steer regulatory decisions? 09:48 - Should the FDA regulate safety or efficacy? 10:31 - Safety, efficacy, and the car analogy 13:04 - Could COVID vaccines have been released earlier? 14:04 - Challenge trials versus large community trials 16:32 - Rolling out vaccines by age and risk 18:05 - Why post COVID myocarditis comparisons are flawed 22:36 - The danger of elite stamped misinformation 24:06 - When medicine became political 26:24 - Why institutions may be too captured to trust 27:24 - The measles death story and missing context 30:17 - Buchanan, Tullock, and the logic of bureaucracy 33:17 - How healthcare swallows trillions with mixed value 35:02 - Why low back surgery is hard to centralize 37:27 - ICD placement and gray zone medicine 39:07 - Who should pay for marginal cancer drugs? 41:10 - Demand subsidies and distorted prices 43:34 - Innovation before large welfare programs 46:53 - Does more money always mean more innovation? 48:48 - Why journalism misses what matters at FDA 51:21 - The No Surprises Act and who really pays 55:42 - Vinay’s broader career path and what comes next 57:34 - Why active clinical practice still matters Co-Host Handles Anish Koka, MD and Anthony DiGiorgio, DO, MHA Show Handle The Doctor’s Lounge Podcast Subscribe Links Spotify: Apple Podcasts: YouTube: Dr. DiGiorgio's project "Off Label Ideas" Dr. DiGiorgio's on Substack

Vinay Prasad: COVID, the FDA, and Why Journalism Keeps Getting Medicine Wrong Dr. Vinay Prasad joins the Doctors Lounge in a recorded in person conversation that moves from his time at the FDA to bigger questions about evidence, incentives, and trust in medicine. The discussion focuses on how regulatory agencies actually function, why public health debates have become so politicized, and whether the current healthcare funding model rewards good care or just expensive care. Timestamps: 00:16 - Why the FDA conversation matters now 02:49 - Why Vinay accepted the DC job 04:02 - What can actually change inside the FDA 05:39 - The Exondys approval and commissioner authority 07:22 - Do appointees really steer regulatory decisions? 09:48 - Should the FDA regulate safety or efficacy? 10:31 - Safety, efficacy, and the car analogy 13:04 - Could COVID vaccines have been released earlier? 14:04 - Challenge trials versus large community trials 16:32 - Rolling out vaccines by age and risk 18:05 - Why post COVID myocarditis comparisons are flawed 22:36 - The danger of elite stamped misinformation 24:06 - When medicine became political 26:24 - Why institutions may be too captured to trust 27:24 - The measles death story and missing context 30:17 - Buchanan, Tullock, and the logic of bureaucracy 33:17 - How healthcare swallows trillions with mixed value 35:02 - Why low back surgery is hard to centralize 37:27 - ICD placement and gray zone medicine 39:07 - Who should pay for marginal cancer drugs? 41:10 - Demand subsidies and distorted prices 43:34 - Innovation before large welfare programs 46:53 - Does more money always mean more innovation? 48:48 - Why journalism misses what matters at FDA 51:21 - The No Surprises Act and who really pays 55:42 - Vinay’s broader career path and what comes next 57:34 - Why active clinical practice still matters Co-Host Handles Anish Koka, MD and Anthony DiGiorgio, DO, MHA Show Handle The Doctor’s Lounge Podcast Subscribe Links Spotify: Apple Podcasts: YouTube: Dr. DiGiorgio's project "Off Label Ideas" Dr. DiGiorgio's on Substack

The Doctor’s Lounge Podcast

27,147 views • 2 months ago

From Addiction to Advocacy: Tom Wolf's Journey In this episode, Anthony DiGiorgio and Anish Koka engage with Tom Wolf, a recovery advocate, who shares his personal journey through addiction, homelessness, and eventual recovery. The conversation delves into the complexities of homelessness, the impact of substance use, and the evolving definitions and policies surrounding addiction treatment. Tom discusses the harm reduction approach, its origins, and its implications, while emphasizing the need for accountability and the role of physicians in addressing the opioid crisis. The episode highlights the importance of lived experiences in shaping drug policy and the ongoing challenges faced by individuals in recovery. In this conversation, Anthony DiGiorgio and Tom Wolf delve into the complexities of addiction treatment, mental health, and the political landscape surrounding these issues. They discuss the challenges of psychiatric holds, the balance between autonomy and compulsion in treatment, and the failures of current drug policies in major cities. The dialogue emphasizes the need for a recovery-oriented system of care and critiques the harm reduction approach, drawing comparisons to international policies, particularly in Portugal. The conversation highlights the intersection of mental health and addiction, the political ramifications of policy failures, and the urgent need for effective solutions to the ongoing drug crisis. Chapters 00:00 Introduction to Recovery Advocacy 00:55 Tom Wolf's Journey Through Addiction 06:33 Finding Recovery and Advocacy 10:08 The Complexity of Homelessness and Addiction 11:22 The Evolving Definition of Homelessness 12:26 The Impact of Substance Use on Housing 15:06 Harm Reduction: A Double-Edged Sword 20:30 The Role of Physicians in Substance Abuse 25:02 The Historical Context of Opioid Prescription 30:02 The Future of Drug Policy and Recovery 34:39 Navigating Psychiatric Holds and Treatment Options 38:30 The Dilemma of Autonomy vs. Compulsion in Treatment 40:40 Evaluating Policy Failures in Major Cities 44:51 Building a Recovery-Oriented System of Care 47:39 Comparing Drug Policies: Lessons from Portugal 49:40 The Intersection of Mental Health and Addiction 51:51 The Political Landscape of Addiction Recovery 56:55 The Challenges of Acknowledging Policy Failures Co-Host Handles Anish Koka, MD and Anthony DiGiorgio, DO, MHA Show Handle The Doctor’s Lounge Podcast Guest Handle/Links T Wolf 🌁 Subscribe Links Spotify: Apple Podcasts: YouTube:

From Addiction to Advocacy: Tom Wolf's Journey In this episode, Anthony DiGiorgio and Anish Koka engage with Tom Wolf, a recovery advocate, who shares his personal journey through addiction, homelessness, and eventual recovery. The conversation delves into the complexities of homelessness, the impact of substance use, and the evolving definitions and policies surrounding addiction treatment. Tom discusses the harm reduction approach, its origins, and its implications, while emphasizing the need for accountability and the role of physicians in addressing the opioid crisis. The episode highlights the importance of lived experiences in shaping drug policy and the ongoing challenges faced by individuals in recovery. In this conversation, Anthony DiGiorgio and Tom Wolf delve into the complexities of addiction treatment, mental health, and the political landscape surrounding these issues. They discuss the challenges of psychiatric holds, the balance between autonomy and compulsion in treatment, and the failures of current drug policies in major cities. The dialogue emphasizes the need for a recovery-oriented system of care and critiques the harm reduction approach, drawing comparisons to international policies, particularly in Portugal. The conversation highlights the intersection of mental health and addiction, the political ramifications of policy failures, and the urgent need for effective solutions to the ongoing drug crisis. Chapters 00:00 Introduction to Recovery Advocacy 00:55 Tom Wolf's Journey Through Addiction 06:33 Finding Recovery and Advocacy 10:08 The Complexity of Homelessness and Addiction 11:22 The Evolving Definition of Homelessness 12:26 The Impact of Substance Use on Housing 15:06 Harm Reduction: A Double-Edged Sword 20:30 The Role of Physicians in Substance Abuse 25:02 The Historical Context of Opioid Prescription 30:02 The Future of Drug Policy and Recovery 34:39 Navigating Psychiatric Holds and Treatment Options 38:30 The Dilemma of Autonomy vs. Compulsion in Treatment 40:40 Evaluating Policy Failures in Major Cities 44:51 Building a Recovery-Oriented System of Care 47:39 Comparing Drug Policies: Lessons from Portugal 49:40 The Intersection of Mental Health and Addiction 51:51 The Political Landscape of Addiction Recovery 56:55 The Challenges of Acknowledging Policy Failures Co-Host Handles Anish Koka, MD and Anthony DiGiorgio, DO, MHA Show Handle The Doctor’s Lounge Podcast Guest Handle/Links T Wolf 🌁 Subscribe Links Spotify: Apple Podcasts: YouTube:

The Doctor’s Lounge Podcast

15,139 views • 1 month ago

Real Doc Speaks: Bureaucracy, Bad Incentives, and the Fight to Keep Doctors in Charge Episode Summary In this special add-on episode, Anish Koka and Anthony DiGiorgio welcome Dr. James O'Leary — a Mayo-trained OB-GYN with forty years of experience, former department chairman, ACO board member, and host of the Real Doc Speaks podcast — for a wide-ranging conversation on the erosion of physician-led care. The trio dissects a tragic Nashville case in which four outpatient knee-replacement patients were injected with potassium phosphate instead of bupivacaine after a multi-step, multi-person medication-verification process failed at every checkpoint, using it as a jumping-off point to discuss "kludgeocracy," alert fatigue, surgical-timeout mission creep, and how doctors who raise safety concerns get labeled disruptive. From there the conversation moves through OB-GYN malpractice and nuclear jury verdicts, Florida's no-fault birth-injury compensation fund as a possible national model, the maze of state-by-state Medicaid reimbursement and its perverse incentives, and nonprofit hospitals' use of stadium sponsorships as a possible anti-kickback violation, before closing with a rapid-fire "hot seat" round covering ACOs, private equity, scope of practice, physician unionization, and single-payer healthcare. Chapters 00:00 Cold open — why isn't Medicaid money reaching physicians? 00:34 Welcoming Dr. James O'Leary (Real Doc Speaks) 02:34 Why physicians need a voice on social media 03:14 The Nashville potassium phosphate medication error 09:52 Would a physician-owned hospital have prevented this? 10:17 "Kludgeocracy" and getting labeled disruptive 14:30 The surgical timeout's mission creep 19:35 EMR alert fatigue and lost safety signals 22:50 Replacing pharmacy techs with better safeguards 24:34 Anish's shift from hospital to outpatient practice 30:19 Malpractice, nuclear verdicts, and OB-GYN 33:50 Florida's no-fault birth-injury compensation model 39:16 Medicaid reimbursement and state-by-state variation 50:33 Nonprofit hospitals, sports sponsorships, and the anti-kickback statute 55:46 Five hot-seat questions for Dr. O'Leary 1:01:51 Direct referrals vs. large health systems 1:03:23 Closing thoughts and where to find Dr. O'Leary Co-Host Handles Anish Koka, MD and Anthony DiGiorgio, DO, MHA Guest Handle Dr. James O'Leary — Real Doc Speaks Show Handle The Doctor’s Lounge Podcast Subscribe Links: Spotify: Apple Podcasts: YouTube:

Real Doc Speaks: Bureaucracy, Bad Incentives, and the Fight to Keep Doctors in Charge Episode Summary In this special add-on episode, Anish Koka and Anthony DiGiorgio welcome Dr. James O'Leary — a Mayo-trained OB-GYN with forty years of experience, former department chairman, ACO board member, and host of the Real Doc Speaks podcast — for a wide-ranging conversation on the erosion of physician-led care. The trio dissects a tragic Nashville case in which four outpatient knee-replacement patients were injected with potassium phosphate instead of bupivacaine after a multi-step, multi-person medication-verification process failed at every checkpoint, using it as a jumping-off point to discuss "kludgeocracy," alert fatigue, surgical-timeout mission creep, and how doctors who raise safety concerns get labeled disruptive. From there the conversation moves through OB-GYN malpractice and nuclear jury verdicts, Florida's no-fault birth-injury compensation fund as a possible national model, the maze of state-by-state Medicaid reimbursement and its perverse incentives, and nonprofit hospitals' use of stadium sponsorships as a possible anti-kickback violation, before closing with a rapid-fire "hot seat" round covering ACOs, private equity, scope of practice, physician unionization, and single-payer healthcare. Chapters 00:00 Cold open — why isn't Medicaid money reaching physicians? 00:34 Welcoming Dr. James O'Leary (Real Doc Speaks) 02:34 Why physicians need a voice on social media 03:14 The Nashville potassium phosphate medication error 09:52 Would a physician-owned hospital have prevented this? 10:17 "Kludgeocracy" and getting labeled disruptive 14:30 The surgical timeout's mission creep 19:35 EMR alert fatigue and lost safety signals 22:50 Replacing pharmacy techs with better safeguards 24:34 Anish's shift from hospital to outpatient practice 30:19 Malpractice, nuclear verdicts, and OB-GYN 33:50 Florida's no-fault birth-injury compensation model 39:16 Medicaid reimbursement and state-by-state variation 50:33 Nonprofit hospitals, sports sponsorships, and the anti-kickback statute 55:46 Five hot-seat questions for Dr. O'Leary 1:01:51 Direct referrals vs. large health systems 1:03:23 Closing thoughts and where to find Dr. O'Leary Co-Host Handles Anish Koka, MD and Anthony DiGiorgio, DO, MHA Guest Handle Dr. James O'Leary — Real Doc Speaks Show Handle The Doctor’s Lounge Podcast Subscribe Links: Spotify: Apple Podcasts: YouTube:

The Doctor’s Lounge Podcast

12,585 views • 1 month ago

The Cost Cure: Ashish Jha's Case for Price Caps, Competition, and Biosurveillance Anthony DiGiorgio and Anish Koka speak with Dr. Ashish Jha, co-founder and CEO of BioRadar, senior fellow at Harvard Belfer Center, and former White House COVID-19 response coordinator, about the future of American healthcare policy. The conversation moves from hospital pricing and insurance design to Medicaid, HSA-based models, and the political realities that shape what reform is actually possible. They also pivot into a second major topic: biothreat detection. Jha explains why he thinks biosurveillance, not just response, will be essential in an era of AI-assisted biological engineering. Timestamps 00:00 - Intro, guest credentials, and the Boston Globe cost cure series 00:33 - Why Jha wrote a 10-part reform series instead of one op-ed 01:54 - Evidence-based ideas that should annoy someone on every side 03:42 - Why state-level health policy matters, not just Washington 04:20 - American healthcare’s core pricing problem 05:58 - Competition, monopolies, and when price regulation enters the picture 06:57 - Scope of practice, insurance design, and administrative burden 08:40 - Indiana’s Medicaid-based hospital pricing experiment 09:47 - Why provider price caps are controversial 11:42 - Site-neutral payments and the hospital lobbying problem 13:30 - Why temporary regulation can bridge a monopoly-heavy market 16:22 - Why payer competition matters before price caps can reach consumers 17:44 - Can temporary government policies ever really be reversed? 20:11 - Tackling the demand-side subsidies that fuel consolidation 22:39 - FTC enforcement and the slow pace of market change 23:53 - Why policy experts should give leaders workable alternatives 26:27 - Hospitals are not villains, but incentives matter 27:32 - Site-neutral payment and physician-owned hospitals as starting points 28:57 - Cash payments, deductibles, and value-based insurance design 29:49 - The outline of a possible deal among hospitals, insurers, and policymakers 33:34 - Medicaid work requirements and what the evidence says 35:36 - Why eligibility should be easier for people who qualify 38:02 - Medicaid as a value statement about universal coverage 40:19 - Program integrity, fraud, and long-term sustainability 43:43 - Why Jha changed his mind on pay-for-performance and EHRs 45:14 - His critique of quality metrics and the value of empirical humility 46:14 - Why HSAs are attractive but imperfect 47:23 - Living under an HSA and why behavior changes 49:47 - Why Medicare for All is politically and operationally hard 50:41 - Uwe Reinhardt, Denmark, and why systems depend on politics and people 53:18 - Why sick people often make irrational cost decisions 57:02 - Smarter copays, true emergencies, and the limits of consumerism 58:24 - Why disagreement should stay respectful and not personal 60:20 - Pivot to bioterrorism and biological weapons 61:07 - Why BioRadar was created and what problem it is solving 63:18 - AI, state actors, and the shrinking barrier to bioweapons 64:18 - Why the risk of an engineered pathogen in the next five years worries Jha 65:31 - Jha’s view that COVID was more likely a lab leak than a natural origin 66:30 - Guardrails around gain-of-function research and Fauci criticism 68:46 - The difference between a dangerous outbreak and a stealth pandemic 71:38 - How biosurveillance can avoid overreaction while still catching real threats 73:13 - Why better surveillance could have changed the COVID response 75:16 - Wrap-up, bipartisanship, and the value of trade-offs Co-Host Handles Anish Koka, MD and Anthony DiGiorgio, DO, MHA Show Handle The Doctor’s Lounge Podcast Subscribe Links Spotify: Apple Podcasts: YouTube:

The Cost Cure: Ashish Jha's Case for Price Caps, Competition, and Biosurveillance Anthony DiGiorgio and Anish Koka speak with Dr. Ashish Jha, co-founder and CEO of BioRadar, senior fellow at Harvard Belfer Center, and former White House COVID-19 response coordinator, about the future of American healthcare policy. The conversation moves from hospital pricing and insurance design to Medicaid, HSA-based models, and the political realities that shape what reform is actually possible. They also pivot into a second major topic: biothreat detection. Jha explains why he thinks biosurveillance, not just response, will be essential in an era of AI-assisted biological engineering. Timestamps 00:00 - Intro, guest credentials, and the Boston Globe cost cure series 00:33 - Why Jha wrote a 10-part reform series instead of one op-ed 01:54 - Evidence-based ideas that should annoy someone on every side 03:42 - Why state-level health policy matters, not just Washington 04:20 - American healthcare’s core pricing problem 05:58 - Competition, monopolies, and when price regulation enters the picture 06:57 - Scope of practice, insurance design, and administrative burden 08:40 - Indiana’s Medicaid-based hospital pricing experiment 09:47 - Why provider price caps are controversial 11:42 - Site-neutral payments and the hospital lobbying problem 13:30 - Why temporary regulation can bridge a monopoly-heavy market 16:22 - Why payer competition matters before price caps can reach consumers 17:44 - Can temporary government policies ever really be reversed? 20:11 - Tackling the demand-side subsidies that fuel consolidation 22:39 - FTC enforcement and the slow pace of market change 23:53 - Why policy experts should give leaders workable alternatives 26:27 - Hospitals are not villains, but incentives matter 27:32 - Site-neutral payment and physician-owned hospitals as starting points 28:57 - Cash payments, deductibles, and value-based insurance design 29:49 - The outline of a possible deal among hospitals, insurers, and policymakers 33:34 - Medicaid work requirements and what the evidence says 35:36 - Why eligibility should be easier for people who qualify 38:02 - Medicaid as a value statement about universal coverage 40:19 - Program integrity, fraud, and long-term sustainability 43:43 - Why Jha changed his mind on pay-for-performance and EHRs 45:14 - His critique of quality metrics and the value of empirical humility 46:14 - Why HSAs are attractive but imperfect 47:23 - Living under an HSA and why behavior changes 49:47 - Why Medicare for All is politically and operationally hard 50:41 - Uwe Reinhardt, Denmark, and why systems depend on politics and people 53:18 - Why sick people often make irrational cost decisions 57:02 - Smarter copays, true emergencies, and the limits of consumerism 58:24 - Why disagreement should stay respectful and not personal 60:20 - Pivot to bioterrorism and biological weapons 61:07 - Why BioRadar was created and what problem it is solving 63:18 - AI, state actors, and the shrinking barrier to bioweapons 64:18 - Why the risk of an engineered pathogen in the next five years worries Jha 65:31 - Jha’s view that COVID was more likely a lab leak than a natural origin 66:30 - Guardrails around gain-of-function research and Fauci criticism 68:46 - The difference between a dangerous outbreak and a stealth pandemic 71:38 - How biosurveillance can avoid overreaction while still catching real threats 73:13 - Why better surveillance could have changed the COVID response 75:16 - Wrap-up, bipartisanship, and the value of trade-offs Co-Host Handles Anish Koka, MD and Anthony DiGiorgio, DO, MHA Show Handle The Doctor’s Lounge Podcast Subscribe Links Spotify: Apple Podcasts: YouTube:

The Doctor’s Lounge Podcast

13,755 views • 1 month ago

If you have a billion dollars, you cannot buy good medicine. Because good doctoring has three components — and none of them are visible from the outside. Technical skill: Can your surgeon actually operate? Other surgeons barely know. You don't. Relational skill: Does your doctor listen? Patients are actually the best judges of this one. Cognitive skill: Can they appraise evidence and apply it correctly to you — not to the average trial patient? No market signal identifies all three. — Dr. Anil Makam, UCSF

If you have a billion dollars, you cannot buy good medicine. Because good doctoring has three components — and none of them are visible from the outside. Technical skill: Can your surgeon actually operate? Other surgeons barely know. You don't. Relational skill: Does your doctor listen? Patients are actually the best judges of this one. Cognitive skill: Can they appraise evidence and apply it correctly to you — not to the average trial patient? No market signal identifies all three. — Dr. Anil Makam, UCSF

The Doctor’s Lounge Podcast

30,448 views • 5 months ago

"No more networks. Just — what's your price?" Rep. Tom Oliverson, MD (practicing anesthesiologist) on where he thinks healthcare is headed: "The future may very well just be direct contracting models... no more networks. It's just — what is your price? What is your cash price?" "This has been a dream of mine for over a decade."

"No more networks. Just — what's your price?" Rep. Tom Oliverson, MD (practicing anesthesiologist) on where he thinks healthcare is headed: "The future may very well just be direct contracting models... no more networks. It's just — what is your price? What is your cash price?" "This has been a dream of mine for over a decade."

The Doctor’s Lounge Podcast

13,608 views • 1 month ago

Subspecialists write guidelines for diseases they've never really seen. Not the full disease — just the tip of the iceberg. The sickest. The most complicated. The referral cases. The hospitalist sees the whole denominator. Every COPD admit. Every run-of-the-mill heart failure. The frail, the comorbid, the ones who will never make it into a trial. "You're seeing the sickest of the sickest — which don't represent the monolith of the disease your recommendations are now applying to." A subspecialist's clinical credentialism is real. So is their selection bias. — Dr. Anil Makam, UCSF

Subspecialists write guidelines for diseases they've never really seen. Not the full disease — just the tip of the iceberg. The sickest. The most complicated. The referral cases. The hospitalist sees the whole denominator. Every COPD admit. Every run-of-the-mill heart failure. The frail, the comorbid, the ones who will never make it into a trial. "You're seeing the sickest of the sickest — which don't represent the monolith of the disease your recommendations are now applying to." A subspecialist's clinical credentialism is real. So is their selection bias. — Dr. Anil Makam, UCSF

The Doctor’s Lounge Podcast

27,018 views • 4 months ago

Every neurosurgeon in America must know what Section 6001 is. Almost none do. Hidden deep within the Affordable Care Act, this one section quietly banned physicians from owning new health systems, cutting off one of the last pathways for independent medicine to compete with billion-dollar hospital monopolies. In this week’s episode of The Doctor’s Lounge, recorded live at PHA Santa Fe, Dr. Lou Tumialan, Chair of the Council of State Neurosurgical Societies, explains how Section 6001 erased physician ownership, created the conditions for mass consolidation, and pushed young doctors into permanent employment. We talk about what independence really means, why the law exists, and how the next generation can take it back. Because the ban wasn’t just legislative... PHA Anthony DiGiorgio, DO, MHA Dutch Rojas Sanat Dixit MD FACS Dan Choi, MD, FAAOS CSNS

Every neurosurgeon in America must know what Section 6001 is. Almost none do. Hidden deep within the Affordable Care Act, this one section quietly banned physicians from owning new health systems, cutting off one of the last pathways for independent medicine to compete with billion-dollar hospital monopolies. In this week’s episode of The Doctor’s Lounge, recorded live at PHA Santa Fe, Dr. Lou Tumialan, Chair of the Council of State Neurosurgical Societies, explains how Section 6001 erased physician ownership, created the conditions for mass consolidation, and pushed young doctors into permanent employment. We talk about what independence really means, why the law exists, and how the next generation can take it back. Because the ban wasn’t just legislative... PHA Anthony DiGiorgio, DO, MHA Dutch Rojas Sanat Dixit MD FACS Dan Choi, MD, FAAOS CSNS

The Doctor’s Lounge Podcast

47,696 views • 11 months ago

Safety and efficacy aren't the same thing. And the FDA still struggles with the harder of the two. Dr. Vinay Prasad, breaking down drug safety like a car: "When you turn the ignition and the car starts... that's a type of safety. The car didn't detonate." Efficacy is driving it a few miles down the road. But real safety — knowing a new heartburn medicine doesn't raise heart attack risk by 4% over the old one — that takes massive, unbiased data. "That is actually something that the FDA, to this day, struggles with."

Safety and efficacy aren't the same thing. And the FDA still struggles with the harder of the two. Dr. Vinay Prasad, breaking down drug safety like a car: "When you turn the ignition and the car starts... that's a type of safety. The car didn't detonate." Efficacy is driving it a few miles down the road. But real safety — knowing a new heartburn medicine doesn't raise heart attack risk by 4% over the old one — that takes massive, unbiased data. "That is actually something that the FDA, to this day, struggles with."

The Doctor’s Lounge Podcast

12,389 views • 2 months ago

Every major study comparing myocarditis risk after the vaccine vs. after COVID has the same flaw, says Dr. Vinay Prasad. The denominator problem: For the vaccine, the denominator is everyone who got the shot. For COVID, it should be everyone who got infected. Instead, it's everyone who got infected AND called a doctor AND went to clinic AND got a PCR test. "So I think all these papers are flawed."

Every major study comparing myocarditis risk after the vaccine vs. after COVID has the same flaw, says Dr. Vinay Prasad. The denominator problem: For the vaccine, the denominator is everyone who got the shot. For COVID, it should be everyone who got infected. Instead, it's everyone who got infected AND called a doctor AND went to clinic AND got a PCR test. "So I think all these papers are flawed."

The Doctor’s Lounge Podcast

11,765 views • 2 months ago

Korea built a no-fault vaccine compensation program that requires autopsy data to attribute cause of death. So they actually did the autopsies. What they found: multiple deaths that were only linked to the vaccine at autopsy. Without the autopsy, the connection would never have been made. The United States has no equivalent system. No autopsies. No attribution. No data. — Dr. Anish Koka

Korea built a no-fault vaccine compensation program that requires autopsy data to attribute cause of death. So they actually did the autopsies. What they found: multiple deaths that were only linked to the vaccine at autopsy. Without the autopsy, the connection would never have been made. The United States has no equivalent system. No autopsies. No attribution. No data. — Dr. Anish Koka

The Doctor’s Lounge Podcast

17,002 views • 3 months ago

There's a pattern playing out in academic medical centers. Cardiac surgery isn't being called as a therapy. It's being called as a last resort. A patient comes in with endocarditis. DNR. DNI. Medical service admits them. A week goes by. They throw an embolus. The toe turns blue. The infection isn't clearing. And then someone says: "If you don't have an operation, you're going to die." And now the patient says yes. "You've been in the hospital for 10 days, you were DNR DNI, and now you're going to have a double valve with a reconstruction of the aortomitral curtain." Wait a second. This isn't a heart team decision. This is what happens when surgery is treated as a disposition for the sickest, most terminal patients — instead of a viable therapy offered early enough to actually matter.

There's a pattern playing out in academic medical centers. Cardiac surgery isn't being called as a therapy. It's being called as a last resort. A patient comes in with endocarditis. DNR. DNI. Medical service admits them. A week goes by. They throw an embolus. The toe turns blue. The infection isn't clearing. And then someone says: "If you don't have an operation, you're going to die." And now the patient says yes. "You've been in the hospital for 10 days, you were DNR DNI, and now you're going to have a double valve with a reconstruction of the aortomitral curtain." Wait a second. This isn't a heart team decision. This is what happens when surgery is treated as a disposition for the sickest, most terminal patients — instead of a viable therapy offered early enough to actually matter.

The Doctor’s Lounge Podcast

21,072 views • 5 months ago

Americans didn't overestimate child COVID deaths by 40%. They overestimated by 40 times. The US media was uniquely alarmist compared to the rest of the world — and the public paid for it with deeply distorted risk perception.

Americans didn't overestimate child COVID deaths by 40%. They overestimated by 40 times. The US media was uniquely alarmist compared to the rest of the world — and the public paid for it with deeply distorted risk perception.

The Doctor’s Lounge Podcast

16,660 views • 4 months ago

The AAMC predicts a shortfall of 86,000 physicians by 2036. Sounds alarming. But who's doing the predicting? "The AAMC is an organization that exists to advocate for the interests of medical schools, which are businesses that are gainfully involved in producing more doctors." You're the carpenter with a hammer. Every problem is gonna be a nail. Yes, population is growing. Yes, the training pipeline has limits. But what doctors do, how they practice, where they practice — none of that is answered by those numbers. Medicine changes. Technology changes. What patients actually need changes. So before accepting the shortage narrative, Carmody says ask a better question: "What are the data that make you think there is a physician shortage?" Not just a number from the AAMC. The actual data.

The AAMC predicts a shortfall of 86,000 physicians by 2036. Sounds alarming. But who's doing the predicting? "The AAMC is an organization that exists to advocate for the interests of medical schools, which are businesses that are gainfully involved in producing more doctors." You're the carpenter with a hammer. Every problem is gonna be a nail. Yes, population is growing. Yes, the training pipeline has limits. But what doctors do, how they practice, where they practice — none of that is answered by those numbers. Medicine changes. Technology changes. What patients actually need changes. So before accepting the shortage narrative, Carmody says ask a better question: "What are the data that make you think there is a physician shortage?" Not just a number from the AAMC. The actual data.

The Doctor’s Lounge Podcast

19,081 views • 5 months ago